Those at risk for transfusion-associated graft-versus-host disease (TA-GVHD) caused by proliferation of donor T lymphocytes Those who are immunocompromised Those receiving intrauterine transfusion Those with hematologic malignancies or solid tumors, including: Sarcoma Neuroblastoma Hodgkin lymphoma Those who are recipients of marrow or peripheral blood stem cell transplantation Those receiving RBCs from blood relatives or human leukocyte antigen-compatible donors Those receiving fludarabine therapy Those receiving granulocyte transfusions
According to the AABB:
Description:
Blood components that contain viable lymphocytes may be irradiated to prevent proliferation of T lymphocytes, which is the immediate cause of TA-GVHD. Irradiated blood is prepared by exposing the component to a radiation source. The standard dose of gamma or X-ray irradiation is 2500 centigray (cGy) targeted to the central portion of the container with a minimum dose of 1500 cGy delivered to any part of the component.
Indications:
Patients at risk for TAGVHD, including: Fetal and neonatal recipients of intrauterine transfusions Selected immunocompromised recipients Recipients of cellular components known to be from a blood relative Recipients who have undergone peripheral blood progenitor cell transplantation Recipients of cellular components whose donor is selected for HLA compatibility and recipients of granulocyte transfusions. Patients receiving purine analogues (eg, fludarabine, cladribine) or certain other biological immunomodulators (eg, alemtuzumab, antithymocyte globulin) who may be at risk for TA-GVHD, depending on clinical factors and the source of the biological agent.